Latest Oncology News

Triplet Therapy Plus Transplantation Prolongs PFS in Multiple Myeloma

August 08, 2022

With a median progression-free survival of 46.2 months in the RVD-alone group and 67.5 months in the transplantation group, lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation extends overall survival in patients with newly diagnosed multiple myeloma.

PARP Inhibitor Regimen Leads to Promising ORR in ES-SCLC

August 08, 2022

The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.

New Strategies Needed for Patients With NSCLC Who Progress on Chemoimmunotherapy

August 08, 2022

Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.